Hepatic in Medical Technology
Navigation Links
Hepatic in Medical Technology
... cardiac symptoms or disease; and renal or hepatic dysfunction. Edema, capillary leak syndrome, ... elevation of serum creatinine or bilirubin and hepatic enzymes in some patients. Monitoring of renal and hepatic function in patients with preexisting renal ...
... reactions that have occurred in adults. hepatic Impairment Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since ... of fluid and electrolyte balance may precipitate hepatic coma. Hypersensitivity Reaction ...
... of the olmesartan medoxomil component. hepatic Impairment Since amlodipine is extensively ... is 56 hours in patients with severely impaired hepatic function, caution should be exercised when administering AZOR to patients with severe hepatic impairment. Laboratory Tests There was a ...
... bleeding, Child-Pugh class C, grade 2 or higher hepatic encephalopathy, ascites requiring therapeutic ... significant reduction in clinical events of hepatic decompensation on protocol-defined secondary ... of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 ...
... any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; ... treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than ... C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha ...
... any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; ... treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than ... C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha ...
... taking dose. Use caution in patients with hepatic impairment. ECGs should be obtained to monitor ... CYP3A4 inhibitors. Use caution in patients with hepatic impairment. Obtain ECGs at baseline, seven days ... abnormality Serum bilirubin and hepatic transaminases The use of Tasigna may result ...
... dose should be used for patients with severe hepatic impairment. Patients with moderate renal ... taking dose. Use with caution in patients with hepatic impairment. ECGs should be obtained to monitor ... CYP3A4 inhibitors. Use caution in patients with hepatic impairment. Obtain ECGs at baseline, seven days ...
... clinical symptoms of liver injury or evidence for hepatic decompensation. Reinitiating treatment with ... when administering PROMACTA to patients with hepatic disease. Use a lower starting dose of PROMACTA in patients with moderate to severe hepatic disease and monitor closely. Bone ...
... cardiac symptoms or disease; and renal or hepatic dysfunction. Edema, capillary leak syndrome, ... elevation of serum creatinine or bilirubin and hepatic enzymes in some patients. Monitoring of renal and hepatic function in patients with preexisting renal or ...
... cardiac symptoms or disease; and renal or hepatic dysfunction. Edema, capillary leak syndrome, ... elevation of serum creatinine or bilirubin and hepatic enzymes in some patients. Monitoring of renal and hepatic function in patients with preexisting renal or ...
... receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used ... count (ANC) cardiac, and up to 3.6% of hepatic transplant patients receiving CellCept 3 g ... of renal, in 1.7% of cardiac, and in 5.4% of hepatic transplant patients treated with CellCept 3 g ...
... receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used ... up to 2.8% of cardiac, and up to 3.6% of hepatic transplant patients receiving CellCept 3 g ... of renal, in 1.7% of cardiac, and in 5.4% of hepatic transplant patients treated with CellCept 3 g ...
... taking dose. Use with caution in patients with hepatic impairment. ECGs should be obtained to monitor ... CYP3A4 inhibitors. Use caution in patients with hepatic impairment. Obtain ECGs at baseline, seven days ... Liver function abnormality Serum bilirubin and hepatic transaminases: Tasigna may result in elevations ...
... adverse reactions that have occurred in adults. hepatic Impairment Thiazides should be used with ... of fluid and electrolyte balance may precipitate hepatic coma. Hypersensitivity Reaction ... (creatinine clearance < 40 mL/min), or in hepatic dysfunction. In patients with possible depletion ...
... VIRAMUNE. Any patient can experience hepatic events; however, female gender and higher CD4+ ... cells/mm3 unless the benefit outweighs the risk. hepatic events are often associated with rash. ... Patients should be intensively monitored for hepatic and skin reactions for the first 18 weeks of ...
... aimed at developing new therapies for hepatic disease." About GT4P GT4P is composed of a ... caution when administering to patients with hepatic or renal insufficiency. AMMONUL(R) may cause ... Use caution when administering to patients with hepatic or renal insufficiency or inborn errors of beta ...
... Doses to Subjects with Mild or Moderate Chronic hepatic Insufficiency" Cethromycin at 300 mg once daily for seven days was well tolerated by subjects with hepatic impairment and subjects with normal hepatic function. The results suggest that no dose ...
... blood chemistry tests to evaluate renal and hepatic function. Dose adjustments to pemetrexed and/or ... See also Warnings and Special Precautions. hepatic impairment: Patients with hepatic impairment, such as bilirubin >1.5-times the ...
... Doses to Subjects with Mild or Moderate Chronic hepatic Insufficiency" Cethromycin at 300 mg once daily for seven days was well tolerated by subjects with hepatic impairment and subjects with normal hepatic function. The results suggest that no dose ...
... taking Afinitor. Afinitor should not be used in patients with severe hepatic impairment. Afinitor may cause fetal harm in pregnant women. The most ... decrease in the recommended dose should be used for patients with severe hepatic impairment. Some GIST patients (5%) were reported to have severe ...
... NUCYNTA(TM) is not recommended in patients with severe renal or hepatic impairment. NUCYNTA(TM) should be used with caution in patients with moderate hepatic impairment. Like other drugs with mu-opioid agonist activity, NUCYNTA(TM) ...
... retention with edema. Use caution when administering to patients with hepatic or renal insufficiency or inborn errors of beta oxidation. The safety or ... ongoing research and development of HPN-100 for urea cycle disorders, hepatic encephalopathy, and other forms of hyperammonemia. Hyperion is ...
... alpha or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in ... dyspnea, pulmonary infiltrates, pneumonia, interstitial pneumonitis, hepatic failure, increases in serum creatinine in patients with renal ...
... alpha or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in ... dyspnea, pulmonary infiltrates, pneumonia, interstitial pneumonitis, hepatic failure, increases in serum creatinine in patients with renal ...
... to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in ... patients before or during treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in ...
... have an increased risk for liver function abnormalities, including severe hepatic adverse events. Post-marketing cases of liver injury, including some ... are no pharmacokinetic or safety data available in patients with severe hepatic impairment. PREZISTA should be used during pregnancy only if the ...
... and possibly other adverse reactions that have occurred in adults. hepatic Impairment Thiazides should be used with caution in patients with ... since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Hypersensitivity Reaction Hypersensitivity reactions to ...
... levels for the Phase III clinical trial of the Company's Percutaneous hepatic Perfusion (PHP) technology for inoperable cancers in the liver. Enrollment ... an unprecedented rate of response in this patient group, the median hepatic progression free survival was reported to be 39 months. The presentation ...
... to Vidaza or mannitol and in patients with advanced malignant hepatic tumors. In clinical studies, the most commonly occurring adverse ... Vidaza is potentially hepatotoxic in patients with severe pre-existing hepatic impairment, caution is needed in patients with liver disease. In addition, ...
... reactions that have occurred in adults. hepatic Impairment Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since ... of fluid and electrolyte balance may precipitate hepatic coma. Hypersensitivity Reaction ...
... of the olmesartan medoxomil component. hepatic Impairment Since amlodipine is extensively ... is 56 hours in patients with severely impaired hepatic function, caution should be exercised when administering AZOR to patients with severe hepatic impairment. Laboratory Tests There was a ...
... bleeding, Child-Pugh class C, grade 2 or higher hepatic encephalopathy, ascites requiring therapeutic ... significant reduction in clinical events of hepatic decompensation on protocol-defined secondary ... of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 ...
... any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; ... treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than ... C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha ...
... any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; ... treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than ... C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha ...
Dr. James F. Pingpank to Present at Leading Regional Therapies Conference
... company testing its proprietary Percutaneous hepatic Perfusion ("PHP(TM)") System for the treatment of ... of High-dose Melphalan (MEL) Administered via hepatic Arterial Infusion for Patients with Unresectable hepatic Metastases from ...... taking dose. Use caution in patients with hepatic impairment. ECGs should be obtained to monitor ... CYP3A4 inhibitors. Use caution in patients with hepatic impairment. Obtain ECGs at baseline, seven days ... abnormality Serum bilirubin and hepatic transaminases The use of Tasigna may result ...
... dose should be used for patients with severe hepatic impairment. Patients with moderate renal ... taking dose. Use with caution in patients with hepatic impairment. ECGs should be obtained to monitor ... CYP3A4 inhibitors. Use caution in patients with hepatic impairment. Obtain ECGs at baseline, seven days ...
... clinical symptoms of liver injury or evidence for hepatic decompensation. Reinitiating treatment with ... when administering PROMACTA to patients with hepatic disease. Use a lower starting dose of PROMACTA in patients with moderate to severe hepatic disease and monitor closely. Bone ...
... cardiac symptoms or disease; and renal or hepatic dysfunction. Edema, capillary leak syndrome, ... elevation of serum creatinine or bilirubin and hepatic enzymes in some patients. Monitoring of renal and hepatic function in patients with preexisting renal or ...
... cardiac symptoms or disease; and renal or hepatic dysfunction. Edema, capillary leak syndrome, ... elevation of serum creatinine or bilirubin and hepatic enzymes in some patients. Monitoring of renal and hepatic function in patients with preexisting renal or ...
... receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used ... count (ANC) cardiac, and up to 3.6% of hepatic transplant patients receiving CellCept 3 g ... of renal, in 1.7% of cardiac, and in 5.4% of hepatic transplant patients treated with CellCept 3 g ...
... receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used ... up to 2.8% of cardiac, and up to 3.6% of hepatic transplant patients receiving CellCept 3 g ... of renal, in 1.7% of cardiac, and in 5.4% of hepatic transplant patients treated with CellCept 3 g ...
... taking dose. Use with caution in patients with hepatic impairment. ECGs should be obtained to monitor ... CYP3A4 inhibitors. Use caution in patients with hepatic impairment. Obtain ECGs at baseline, seven days ... Liver function abnormality Serum bilirubin and hepatic transaminases: Tasigna may result in elevations ...
... adverse reactions that have occurred in adults. hepatic Impairment Thiazides should be used with ... of fluid and electrolyte balance may precipitate hepatic coma. Hypersensitivity Reaction ... (creatinine clearance < 40 mL/min), or in hepatic dysfunction. In patients with possible depletion ...
... VIRAMUNE. Any patient can experience hepatic events; however, female gender and higher CD4+ ... cells/mm3 unless the benefit outweighs the risk. hepatic events are often associated with rash. ... Patients should be intensively monitored for hepatic and skin reactions for the first 18 weeks of ...
... aimed at developing new therapies for hepatic disease." About GT4P GT4P is composed of a ... caution when administering to patients with hepatic or renal insufficiency. AMMONUL(R) may cause ... Use caution when administering to patients with hepatic or renal insufficiency or inborn errors of beta ...
Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
... B or C co-infection or patients with mild hepatic impairment. -- Liver function tests should be ... for reports of: -- Clinical hepatitis and hepatic decompensation including some fatalities. ... with reports of clinical hepatitis and hepatic decompensation, including some fatalities. Extra ...... Doses to Subjects with Mild or Moderate Chronic hepatic Insufficiency" Cethromycin at 300 mg once daily for seven days was well tolerated by subjects with hepatic impairment and subjects with normal hepatic function. The results suggest that no dose ...
... blood chemistry tests to evaluate renal and hepatic function. Dose adjustments to pemetrexed and/or ... See also Warnings and Special Precautions. hepatic impairment: Patients with hepatic impairment, such as bilirubin >1.5-times the ...
... Doses to Subjects with Mild or Moderate Chronic hepatic Insufficiency" Cethromycin at 300 mg once daily for seven days was well tolerated by subjects with hepatic impairment and subjects with normal hepatic function. The results suggest that no dose ...
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
... seen with analysis of adverse events. Shifts in hepatic and renal laboratory values during treatment with ... Isolated cases of clinically significant hepatic dysfunction, hepatitis, worsening hepatic failure, renal dysfunction, acute renal failure, ...... taking Afinitor. Afinitor should not be used in patients with severe hepatic impairment. Afinitor may cause fetal harm in pregnant women. The most ... decrease in the recommended dose should be used for patients with severe hepatic impairment. Some GIST patients (5%) were reported to have severe ...
... NUCYNTA(TM) is not recommended in patients with severe renal or hepatic impairment. NUCYNTA(TM) should be used with caution in patients with moderate hepatic impairment. Like other drugs with mu-opioid agonist activity, NUCYNTA(TM) ...
... retention with edema. Use caution when administering to patients with hepatic or renal insufficiency or inborn errors of beta oxidation. The safety or ... ongoing research and development of HPN-100 for urea cycle disorders, hepatic encephalopathy, and other forms of hyperammonemia. Hyperion is ...
... alpha or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in ... dyspnea, pulmonary infiltrates, pneumonia, interstitial pneumonitis, hepatic failure, increases in serum creatinine in patients with renal ...
Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
... ongoing research and development of HPN-100 for urea cycle disorders, hepatic encephalopathy, and other forms of hyperammonemia. About BUPHENYL(R) ... retention with edema. Use caution when administering to patients with hepatic or renal insufficiency or inborn errors of beta oxidation. The safety or ...... alpha or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in ... dyspnea, pulmonary infiltrates, pneumonia, interstitial pneumonitis, hepatic failure, increases in serum creatinine in patients with renal ...
FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
... caution in patients with pancreatic or biliary tract disease, and moderate hepatic impairment. Because elderly patients are more likely to have decreased renal and hepatic function, consideration should be given to starting elderly patients with ...... to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in ... patients before or during treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in ...
GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
... our medicine is very important to us. On a continual basis, an external hepatic Safety Board reviews any adverse event report received by GSK of liver ... as July 2008, this panel of experts continued to endorse a favorable hepatic safety profile for AVANDIA. Patients being treated with AVANDIA or other ...... have an increased risk for liver function abnormalities, including severe hepatic adverse events. Post-marketing cases of liver injury, including some ... are no pharmacokinetic or safety data available in patients with severe hepatic impairment. PREZISTA should be used during pregnancy only if the ...
... and possibly other adverse reactions that have occurred in adults. hepatic Impairment Thiazides should be used with caution in patients with ... since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Hypersensitivity Reaction Hypersensitivity reactions to ...
... levels for the Phase III clinical trial of the Company's Percutaneous hepatic Perfusion (PHP) technology for inoperable cancers in the liver. Enrollment ... an unprecedented rate of response in this patient group, the median hepatic progression free survival was reported to be 39 months. The presentation ...
PEGASYS(R)/COPEGUS(R) Show Benefit in Hard-to-Treat Latino Population with Hepatitis C
... to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in ... patients before or during treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in ...Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
... be expected with AZOR because of the olmesartan medoxomil component. hepatic Impairment Since amlodipine is extensively metabolized by the liver and ... should be exercised when administering AZOR to patients with severe hepatic impairment. Laboratory Tests There was a greater decrease in ...Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
... proposed by the Company has a primary endpoint of a two-stage drop in hepatic encephalopathy and its secondary endpoints include several survival based endpoints. The Company is refining its position that a two-stage drop in hepatic encephalopathy is clinically meaningful and an appropriate primary ...Roche responds to announcement of 'IDEAL' hepatitis C trial results
... to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in ... patients before or during treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in ...... to Vidaza or mannitol and in patients with advanced malignant hepatic tumors. In clinical studies, the most commonly occurring adverse ... Vidaza is potentially hepatotoxic in patients with severe pre-existing hepatic impairment, caution is needed in patients with liver disease. In addition, ...
Other ContentsbloatingbloatingblockedblockedblockedblockedblockedblockedblockedclotsclotsclotsclotsdifferentialdifferentialdifferentialdifferentialdifferentialdifferentialdifferentialdifferentialdifferentialstudiesstudiesstudiesstudiesstudiesstudiesstudiesstudiesstudiesstudiesgasesgasesgasesgasesgasesgasesgasesblurredblurredblurredblurredOther TagsCTPTREMTREMTREMTREMTREMAntigenixCTICTICTICTICTICTICTICTICTIOther Tagsgoing 2going 3going 4going 5going 6going 7going 8going 9going 10drop 2drop 3drop 4drop 5drop 6drop 7drop 8drop 9drop 10breakdown 2breakdown 3breakdown 4breakdown 5breakdown 6probable 2probable 3probable 4probable 5third 2third 3third 4third 5third 6third 7third 8third 9third 10one 2one 3one 4one 5one 6one 7one 8one 9one 10finds 2finds 3finds 4finds 5team 2team 3team 4team 5team 6team 7team 8team 9team 10
(Date:3/16/2010)... Tourists wanting to watch and swim with dolphins are now ... protect both the animals and the local communities whose livelihoods ... off the coast of Zanzibar has found that the many ... preventing them from resting, feeding and nurturing their young. , ... also highlights swimming with dolphins in particular where tourists ...
(Date:3/16/2010)... mashup of monster movies, but palaeontologists have discovered evidence ... a killing that took place 4 million years ago. ... rare, but by careful, forensic-style analysis of bite marks ... based in Pisa, Italy, have reconstructed the events that ... the probably identity of the killer: a 4 m ...
(Date:3/16/2010)... the largest die-off of great whales ever recorded? , ... health experts from the Wildlife Conservation Society have joined ... the International Whaling Commission on the Patagonian coast of ... mystery. , At issue is the long-term conservation of ... conservation success stories and the focus of a thriving ...
Breaking Biology News(10 mins):Thrill-seeking holidaymakers are putting dolphins at risk 2Jaws -- 4 million BC 2Experts gather to solve mystery of largest recorded die-off of great whales 2Experts gather to solve mystery of largest recorded die-off of great whales 3HealthWarehouse com Inc Announces Second Quarter Financial Results 3B Revenues Increase Significantly Over Second Quarter 2008 55274 1HealthWarehouse com Inc Announces Second Quarter Financial Results 3B Revenues Increase Significantly Over Second Quarter 2008 55274 2HealthWarehouse com Inc Announces Second Quarter Financial Results 3B Revenues Increase Significantly Over Second Quarter 2008 55274 3Just in Time for Allergy Season ZYRTEC 28R 29 Provides New Solutions for Adults and Children 55272 1Just in Time for Allergy Season ZYRTEC 28R 29 Provides New Solutions for Adults and Children 55272 2Just in Time for Allergy Season ZYRTEC 28R 29 Provides New Solutions for Adults and Children 55272 3Just in Time for Allergy Season ZYRTEC 28R 29 Provides New Solutions for Adults and Children 55272 4Employers Face 10 5 Percent Health Care Cost Increases Says Aon Consulting 55270 1Employers Face 10 5 Percent Health Care Cost Increases Says Aon Consulting 55270 2Employers Face 10 5 Percent Health Care Cost Increases Says Aon Consulting 55270 3Employers Face 10 5 Percent Health Care Cost Increases Says Aon Consulting 55270 4Employers Face 10 5 Percent Health Care Cost Increases Says Aon Consulting 55270 5Employers Face 10 5 Percent Health Care Cost Increases Says Aon Consulting 55270 6(Date:3/17/2010)... essential for pregnant women, researchers say , , WEDNESDAY, March ... during pregnancy may suffer more severe brain damage than ... study suggests. , "We know that alcohol exposure is ... lifelong brain, cognitive and behavioral problems," research team leader ... said in a news release. "In this study, we ...
(Date:3/17/2010)... largest HVAC/R exposition comes to Las Vegas for the first ... ... (Vocus) March 17, 2010, , , , ,Calendar Notice, , ... ,Las Vegas Convention Center ,Las Vegas, Nevada , www.ahrexpo.com , ... , The ...
(Date:3/17/2010)... Massage Prep, the massage industry,s leading ... study program for the NCETM , NCETMB ... 30 animated muscle tutorials, 25 interactive study guides, and ... These features, which include narration for auditory learners, further ... rigorous NCETM , NCETMB and ...
(Date:3/17/2010)... for U.S. HealthWorks Medical Group participated in the 2nd U.S. ... research and delivery. , ... Pasadena, ... and affiliated clinicians for U.S. HealthWorks Medical Group ... CA featuring innovators in healthcare research and delivery., , ,U.S. ...
(Date:3/17/2010)... requiring seat use , ... , , ... ... ... 50 states have some type of child safety seat law, 28 of which require kids to use child safety seats or booster seats through age 8 to ...
Breaking Medicine News(10 mins):Health News:Meth Exposure May Be Worse for Fetus Than Alcohol 2Health News:2011 AHR EXPO Calendar Listing 2Health News:2011 AHR EXPO Calendar Listing 3Health News:2011 AHR EXPO Calendar Listing 4Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 2Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 3Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 4Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 5Health News:Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx 6Health News:Innovative Healthcare Symposium Held By U.S. HealthWorks 2Health News:Unaware of Laws, Many Parents Not Using Booster Seats for Older Children 2Health News:Unaware of Laws, Many Parents Not Using Booster Seats for Older Children 3Health News:Unaware of Laws, Many Parents Not Using Booster Seats for Older Children 4Health News:Unaware of Laws, Many Parents Not Using Booster Seats for Older Children 5Health News:Unaware of Laws, Many Parents Not Using Booster Seats for Older Children 6Health News:Unaware of Laws, Many Parents Not Using Booster Seats for Older Children 7[0] Meth Exposure May Be Worse for Fetus Than Alcohol[0] 2011 AHR EXPO Calendar Listing[0] Massage Prep(TM) Announces New Interactive Tutorials for NCETM, NCETMB and MBLEx[0] Innovative Healthcare Symposium Held By U.S. HealthWorks [0] Unaware of Laws, Many Parents Not Using Booster Seats for Older Children
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |